您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (12): 23-28.doi: 10.6040/j.issn.1671-7554.0.2020.0817

• • 上一篇    下一篇

miR-203靶向Survivin抑制卵巢癌细胞增殖、迁移与侵袭

王宝金1,赵欣欣1,李霞1,马倩1,王新月1,孙阳2,史中娜1   

  1. 1.郑州大学第三附属医院妇科, 河南省卵巢恶性肿瘤国际联合实验室, 河南 郑州 450052;2.福建省立医院妇科, 福建 福州 350001
  • 发布日期:2020-12-08
  • 通讯作者: 王宝金. E-mail:307797362@qq.com
  • 基金资助:
    河南省科技计划项目(192102310067,GHB2019048)

miR-203 targeting Survivin to inhibit the proliferation, migration and invasion of ovarian cancer cells

WANG Baojin1, ZHAO Xinxin1, LI Xia1, MA Qian1, WANG Xinyue1, SUN Yang2, SHI Zhongna1   

  1. 1. Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, Henan International Joint Laboratory of Ovarian Malignancies, Zhengzhou 450052, Henan, China;
    2. Department of Gynecology, Fujian Provincial Hospital, Fuzhou 350001, Fujian, China
  • Published:2020-12-08

PDF (PC)

240

摘要： 目的 探讨miR-203靶向抑制Survivin对卵巢癌SKOV3及OVCAR3细胞增殖、迁移及侵袭的影响。 方法 构建过表达miR-203、Survivin及空白对照组的慢病毒载体,转染卵巢癌SKOV3和OVCAR3细胞,嘌呤霉素筛选后构建空白对照组、过表达miR-203组、过表达Survivin组及过表达miR-203联合Survivin组卵巢癌细胞系。Western blotting方法测定各组卵巢癌细胞中Survivin及上皮-间质转化(EMT)相关蛋白的表达;MTT和平板克隆实验检测卵巢癌细胞增殖能力的改变;Transwell实验检测对细胞迁移和侵袭能力的影响。 结果 (1) 过表达miR-203抑制Survivin的表达及EMT(P<0.05);(2) MTT、平板克隆实验及transwell实验显示,与空白对照组相比,过表达miR-203组能够抑制卵巢癌细胞的增殖、迁移和侵袭(P<0.05);而过表达Survivin逆转了miR-203对卵巢癌的抑制作用(P<0.05)。 结论 miR-203通过靶向Survivin抑制EMT从而抑制卵巢癌的增殖、迁移及侵袭,miR-203/Survivin/EMT轴有望成为卵巢癌治疗的新靶点。

关键词: 卵巢癌, miR-203, Survivin, 上皮-间质转化

Abstract: Objective To investigate the effects of miR-203 targeting Survivin on the proliferation, migration and invasion of ovarian cancer cells SKOV3 and OVCAR3. Methods After miR-203 over-expressing group, Survivin over-expressing group and black control group of lentiviral vectors were constructed, the SKOV3 and OVCAR3 cells were transfected. After puromycin screening, the blank control group, miR-203 over-expressing group, Survivin over-expressing group, and miR-203 over-expressing plus Survivin group were established. The expressions of Survivin and epithelial-mesenchymal transition(EMT)-related proteins in each group were detected with Western blotting. The proliferation of cells was detected with MTT and plate clone formation assay. The cell migration and invasion were detected with Transwell assay. Results miR-203 over-expression inhibited the expressions of Survivin and EMT(P<0.05). MTT, plate clone formation and Transwell assay illustrated that, compared with the blank control group, the miR-203 over-expressing group had inhibited cell proliferation, migration, and invasion(P<0.05), while the Survivin over-expressing group reversed the inhibitory effects of miR-203(P<0.05). Conclusion miR-203 can inhibit EMT by targeting Survivin to inhibit the proliferation, migration, and invasion of ovarian cancer cells. The miR-203/Survivin/EMT axis is expected to be a new target for the treatment of ovarian cancer.

Key words: Ovarian cancer, miR-203, Survivin, Epithelial-mesenchymal transition

中图分类号: 

  • R737.31
[1] 陆衡, 刘延国, 李曙光, 等. YKL-40对卵巢癌SKOV-3细胞迁移能力的影响[J]. 山东大学学报(医学版), 2017, 55(1): 33-38. LU Heng, LIU Yanguo, LI Shuguang, et al. Regulation of epithelial ovarian carcinoma SKOV-3 cell migration by YKL-40 and the underlying mechanism [J]. Journal of Shandong University, 2017, 55(1): 33-38.
[2] Wu X, Liu X. Analysis of the expression of D-dimer, CD147 and miR203 and their correlation in gastric cancer[J]. Pak J Med Sci, 2019, 35(2): 443-447.
[3] Piasecka D, Braun M, Kordek R, et al. MicroRNAs in regulation of triple-negative breast cancer progression[J]. J Cancer Res Clin Oncol, 2018, 144(8): 1401-1411.
[4] You A, Fu L, Li Y, et al. MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3[J]. Cell Cycle, 2020, 19(10): 1105-1121.
[5] Wang Q, Yang G, Jiang Y, et al. XB130, regulated by miR-203, miR-219, and miR-4782-3p, mediates the proliferation and metastasis of non-small-cell lung cancer cells[J]. Mol Carcinog, 2020, 59(5): 557-568.
[6] Zeng S, Liu S, Feng J, et al. MicroRNA-32 promotes ovarian cancer cell proliferation and motility by targeting SMG1[J]. Oncol Lett, 2020, 20(1): 733-741.
[7] Zhang Y, Zhou SY, Yan HZ, et al. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1[J]. Sci Rep, 2016, 6: 19995. doi:10.1038/srep19995.
[8] Le F, Luo P, Ouyang Q, et al. LncRNA WT1-AS downregulates Survivin by upregulating miR-203 in papillary thyroid carcinoma[J]. Cancer Manag Res, 2020, 12: 443-449. doi: 10.2147/CMAR.S232294.eCollection 2020.
[9] Wang B, Li X, Zhao G, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway[J]. J Exp Clin Cancer Res, 2018, 37(1): 235-243.
[10] Qian XQ, Tang SS, Shen YM, et al. Notch1 affects chemo-resistance through regulating epithelial-mesenchymal transition(EMT)in epithelial ovarian cancer cells[J]. Int J Med Sci, 2020, 17(9): 1215-1223.
[11] Scalici JM, Arapovic S, Saks EJ, et al. Mesothelium expression of vascular cell adhesion molecule-1(VCAM-1)is associated with an unfavorable prognosis in epithelial ovarian cancer(EOC)[J]. Cancer, 2017, 123(6): 977-984.
[12] Chen X, Zhang J, Zhang Z, et al. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma[J]. Hum Pathol, 2013, 44(11): 2373-2384.
[13] Ghafouri-Fard S, Shoorei H, Taheri M. miRNA profile in ovarian cancer[J]. Exp Mol Pathol, 2020, 113: 104381. doi:10.1016/j.yexmp.2020.104381.
[14] Kim JS, Choi DW, Kim CS, et al. MicroRNA-203 induces apoptosis by targeting bmi-1 in YD-38 oral cancer cells[J]. Anticancer Res, 2018, 38(6): 3477-3485.
[15] Zhang K, Dai L, Zhang B, et al. miR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells[J]. J Cell Physiol, 2015, 230(4): 903-910.
[16] Gao P, Wang S, Jing F, et al. microRNA-203 suppresses invasion of gastric cancer cells by targeting ERK1/2/Slug/ E-cadherin signaling[J]. Cancer Biomark, 2017, 19(1): 11-20.
[17] Deng B, Wang B, Fang J, et al. MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2[J]. Sci Rep, 2016, 6: 28301. doi:10.1038/srep28301.
[18] Chi Y, Jin Q, Liu X, et al. miR-203 inhibits cell proliferation, invasion, and migration of non-small-cell lung cancer by downregulating RGS17[J]. Cancer Sci, 2017, 108(12): 2366-2372.
[19] Shen J, Zhang J, Xiao M, et al. miR-203 Suppresses bladder cancer cell growth and targets twist[J]. Oncol Res, 2018, 26(8): 1155-1165.
[20] Lin J, Wang L, Gao J, et al. MiR-203 inhibits estrogen-induced viability, migration and invasion of estrogen receptor α-positive breast cancer cells[J]. Exp Ther Med, 2017, 14(3): 2702-2708.
[21] Martínez-García D, Manero-Rupérez N, Quesada R, et al. Therapeutic strategies involving survivin inhibition in cancer[J]. Med Res Rev, 2019, 39(3): 887-909.
[22] He XJ, Zhang Q, Ma LP, et al. Aberrant alternative polyadenylation is responsible for Survivin up-regulation in ovarian cancer[J]. Chin Med J(Engl), 2016, 129(10): 1140-1146.
[23] Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018, 13: 395-412. doi: 10.1146/annurev-pathol-020117-043854.
[24] Qian XQ, Tang SS, Shen YM, et al. Notch1 affects chemo-resistance through regulating epithelial-mesenchymal transition(EMT)in epithelial ovarian cancer cells[J]. Int J Med Sci, 2020, 17(9): 1215-1223.
[25] Wang Z, Liu Y, Wang M, et al. Effects of miR-492 on migration, invasion, EMT and prognosis in ovarian cancer by targeting SOX7[J]. J buon, 2020, 25(2): 797-804.
[26] Zhao G, Guo Y, Chen Z, et al. miR-203 functions as a tumor Suppressor by inhibiting epithelial to mesenchymal transition in ovarian cancer[J]. J Cancer Sci Ther, 2015, 7(2): 34-43.
[1] 王琳琳 孙美丽 孙玉萍 张楠 刘传勇. 中心体α-微管蛋白、γ-微管蛋白在脑胶质瘤中的表达及其与Survivin表达的相关性研究[J]. 山东大学学报(医学版), 2209, 47(6): 103-.
[2] 林雪艳,李春艳,侯小满,田永杰. PARP-1及EMT标志物在子宫腺肌病在位及异位内膜中的表达[J]. 山东大学学报（医学版）, 2017, 55(9): 36-40.
[3] 陆衡,刘延国,李曙光,陈晓康,田琦,衣翠华,王秀问. YKL-40对卵巢癌SKOV-3细胞迁移能力的影响[J]. 山东大学学报（医学版）, 2017, 55(1): 33-38.
[4] 赵云霞,宋静,张灿灿,林雪艳,尉蔚,田永杰. CXXC4增强上皮性卵巢癌细胞对化疗药物的敏感性[J]. 山东大学学报（医学版）, 2016, 54(3): 24-29.
[5] 徐志宏,吴小华,姚铁柱,王晓翔,段晓阳,史健. mir-99a的表达与上皮性卵巢癌患者预后的关系[J]. 山东大学学报（医学版）, 2016, 54(3): 77-80.
[6] 徐志宏,姚铁柱,吴小华. 同时性原发性乳腺癌合并原发性双侧卵巢癌1例[J]. 山东大学学报（医学版）, 2016, 54(1): 94-96.
[7] 张晓晖, 颜磊, 齐莎莎, 路真真, 李明江, 赵兴波. 子宫内膜腺癌中EMT的发生及miR200a/ZEB1信号通路在该过程中发挥的作用[J]. 山东大学学报（医学版）, 2015, 53(7): 48-52.
[8] 谷旭, 王夏青, 任万华, 秦成勇, 韩国庆. NPRL2、Survivin在肝细胞肝癌中的表达及其临床意义[J]. 山东大学学报（医学版）, 2015, 53(6): 68-72.
[9] 李红霞, 董蕾, 姜炅, 王新阳. 酪酪肽对胰腺癌Miapaca-2细胞凋亡的影响[J]. 山东大学学报（医学版）, 2015, 53(12): 7-11.
[10] 仇会会1，叶丽平1，温有锋2，李丹1，宋佳1. IL-6对卵巢癌细胞bcl-2、cyclinD1和VEGF表达的影响[J]. 山东大学学报（医学版）, 2014, 52(6): 17-21.
[11] 吴金华1，杨细虎1，刘振中2，丁晓军1，许建辉1. 凋亡抑制因子Survivin在口腔鳞癌中的表达及其意义[J]. 山东大学学报（医学版）, 2014, 52(4): 89-92.
[12] 李燕，尉蔚，吕树卿，田永杰. PARP-1对卵巢癌血管生成的影响[J]. 山东大学学报（医学版）, 2014, 52(4): 97-101.
[13] 张淼慈, 李萍, 哈敏文. 重组人血管内皮抑素联合吉西他滨治疗铂类耐药复发卵巢癌的临床观察[J]. 山东大学学报（医学版）, 2014, 52(11): 55-59.
[14] 朱守荣1，张芮2，曹永倩1，冯璋1，王一兵1. 慢病毒载体靶向携带survivin-siRNA对恶性黑色素瘤A375细胞的影响[J]. 山东大学学报(医学版), 2013, 51(5): 54-57.
[15] 张艳霞1，章培军2，闫燕艳3，段爱旭4，李加善2，牛三强5. Ki-67、PCNA 和Survivin在胃肠道间质瘤组织中的表达[J]. 山东大学学报(医学版), 2013, 51(1): 67-70.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发